Ovarian Cancer — Microlearning Activity 4: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer Video

Featuring an interview with Dr Erica Mayer, including the following topics: Risk Assessment and Genomic Assays for Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer (0:00) Investigator Survey Results on Risk Assessment and Genomic Assays (20:07) Adjuvant CDK4/6 Inhibitors for High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer (24:30) Investigator Survey Results on Adjuvant CDK4/6 Inhibitors (30:42) Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (32:07) Investigator Survey Results on Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (37:44) Adjuvant Oral Selective Estrogen Receptor Degraders (SERDs) for HR-Positive, HER2-Negative Localized Breast Cancer (39:05) Investigator Survey Results on Adjuvant Oral SERDs (43:02) Discussion of Questions from the Community (45:00) CME information and select publications

Featuring perspectives from Dr Lindsey Roeker, including the following topics: Case: A man in his mid 60s with TP53-aberrant chronic lymphocytic leukemia (CLL) with extensive marrow infiltration receives first-line venetoclax/obinutuzumab and experiences an excellent response (0:00) Case: A man in his late 70s with small lymphocytic lymphoma (SLL) and cardiovascular comorbidities requiring verapamil and anticoagulation receives acalabrutinib/venetoclax; Case: A man in his early 80s with SLL receives zanubrutinib/sonrotoclax as part of the CELESTIAL-TNCLL trial (14:46) Case: A man in his late 70s with progressive CLL worsening after a skiing injury receives acalabrutinib/venetoclax as part of the MAJIC trial (22:37) CME information and select publications

Featuring perspectives from Dr Lindsey Roeker, including the following topics: Consensus Approach to optimizing front-line treatment (0:00) Emerging role of sonrotoclax (8:39) Bruton tyrosine kinase inhibitor monotherapy for older patients; discontinuation (14:48) Evolving role of minimal residual disease assessment (19:16) CME information and select publications

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Case: A woman in her late 60s with a germline BRCA2 mutation and heavily pretreated ovarian cancer receives weekly nab paclitaxel and relacorilant — Angeles Alvarez Secord, MD, MHSc (0:00) CME information and select publications

Featuring an interview with Prof Karim Fizazi, including the following topics: Perspectives on the PROTEUS Phase III trial evaluating the addition of apalutamide to standard therapy for high-risk localized prostate cancer (0:00) Mechanism of action of opevesostat and potential role in castration-resistant prostate cancer with androgen receptor mutations (15:37) Perspectives on alpha- and beta-emitting radiopharmaceuticals in the treatment of prostate cancer (22:47) Novel antibody-drug conjugates and proteolysis-targeting chimeras (30:43) Treatment approaches for metastatic hormone-sensitive prostate cancer — de novo symptomatic presentation versus PSMA-only metastatic recurrence after local therapy (34:51) Role of intermittent therapy in the treatment of prostate cancer (38:48) Treatment intensification approaches in prostate cancer (41:38) Case: A man in his late 60s with de novo PSMA PET-positive metastatic castration-sensitive prostate cancer (45:25) CME information and select publications